Cipla Invests Rs 5 Cr in iCaltech to Boost Respiratory Diagnostics

In a strategic effort to enhance its presence in respiratory healthcare, Cipla has made an investment of Rs. 5 crore in Bengaluru-based medical device firm iCaltech Innovations. The pharma giant has entered into definitive agreements with iCaltech Innovations to acquire a voting stake of 20 percent through the subscription of 1,50,820 optionally convertible preference shares and one equity share of face value of Rs. 10 each.

The investment, which will be done in a month, is part of Cipla's larger strategy of strengthening its business in the digital, devices, and diagnostics (D3) space, most notably in the respiratory segment, where the company already has significant expertise.

Achin Gupta, Global Chief Operating Officer of Cipla said, "As respiratory leaders, our choice to invest in iCaltech is a testament to the fact that Cipla is committed to driving respiratory diagnostics forward. In an effort to bridge the current gap in the existing ecosystem, our strategic investment will empower iCaltech to further scale and advance innovative devices."

Key Highlights:

• Cipla invests Rs. 5 crore for a 20 percent stake in iCaltech Innovations
• Partnership boosts Cipla’s respiratory diagnostics capabilities
• iCaltech reported Rs. 6.7 crore revenue in FY24–25

iCaltech Innovations specializes in design, development, and commercialization of advanced diagnostic devices for respiratory health issues. The organization has reported FY24-25 revenue of Rs. 6.70 crore.

Also Read: Top Trends in Nepal's Hospitality Sector

Though financial details above the Rs. 5 crore investment have not been shared, Cipla stressed that strategic collaborations such as this are central to driving its innovation engine. The partnership will further enhance Cipla's leadership in respiratory care and enable integrated solutions for patients.

The deal reflects Cipla's continued focus on accelerating vital healthcare technologies and meeting unmet clinical needs.